cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25402/nmt.24763386.v1
title: Comparison of diagnostic routines for suspected Alzheimer’s disease patients in US–American and German primary care supplement

description: <b>Aim: </b>Thorough diagnostics are a prerequisite for the optimal treatment of Alzheimer’s disease (AD). Biomarker-based diagnostics are standard in academia, data on practitioners’ diagnostic workups is scarce. <b>Materials & methods:</b> Surveys in German and US healthcare providers (HCP) were conducted regarding diagnostics in presumed AD patients. A subsample of 153 German and 88 US professionals was analyzed in detail. <b>Results: </b>Fewer German physicians conduct AD diagnostics themselves compared with US colleagues (67% vs 99%; p &lt; 0.0001). German doctors more often order diagnostics at other institutions (65% vs 45%; p &lt; 0.005). No significant differences were found regarding the type of diagnostics ordered at other institutions. <b>Conclusion</b><b>:</b> Diagnostic routines for suspected AD patients differ between German and US–American healthcare providers. <b>Plain language summary: </b>It is important to conduct the best-possible tests to come to a correct diagnosis of Alzheimer’s disease (AD). This ensures choosing the optimal treatment. In academic surroundings such as specialized memory clinics, so called biomarkers (found for example in blood) are an important component in finding the correct diagnosis. However, there is limited data on the methods healthcare providers (HCP) use in their everyday clinical practice. With this study, we aimed to get a clearer picture of the differences in the diagnostic routines for potential AD patients implemented by HCPs in two highincome countries, Germany and the USA. We conducted two surveys in 500 German and 100 US HCPs on their AD-diagnostic routines. A comparable subsample of 153 German and 88 US professionals was analyzed in detail.We found that fewer German physicians conduct AD diagnostics themselves compared with their US–American colleagues (67% vs 99%). The other way around, German doctors more often order diagnostics at other institutions (65% vs 45%). However, there were no significant differences in the type of diagnostic procedures ordered at other institutions. In conclusion, diagnostic routines for suspected AD patients differ between German and US–American healthcare providers, such as biomarkerbased diagnostics, which German physicians significantly perform less often.
DOI: 10.25402/nmt.25102121
title: An innovative approach to recruiting participants for dementia research: primary care and researcher perspectives - supplementary file

description: <b>Aim: </b>To describe clinician and researcher perceptions of a new, patient preference focused approach to recruiting patients for research from primary care-based memory clinics. <b>Methods: </b>Memory clinic clinicians completed a survey and key informants completed an individual interview to gather their perceptions of this new program. <b>Results: </b>Themajority of clinicians were ‘satisfied’ or ‘very satisfied’with this recruitment approach and indicated that this approach would have minimal negative impact on patient care or create conflict of interest. Key informants valued the program for its patient-centred approach, the integration of research into care and potential for increased recruitment. <b>Discussion: </b>These findings are suggestive of support for this recruitment approach. Pilot testing will inform feasibility, effectiveness and process improvements.
DOI: 10.25402/nmt.25102121.v1
title: An innovative approach to recruiting participants for dementia research: primary care and researcher perspectives - supplementary file

description: <b>Aim: </b>To describe clinician and researcher perceptions of a new, patient preference focused approach to recruiting patients for research from primary care-based memory clinics. <b>Methods: </b>Memory clinic clinicians completed a survey and key informants completed an individual interview to gather their perceptions of this new program. <b>Results: </b>Themajority of clinicians were ‘satisfied’ or ‘very satisfied’with this recruitment approach and indicated that this approach would have minimal negative impact on patient care or create conflict of interest. Key informants valued the program for its patient-centred approach, the integration of research into care and potential for increased recruitment. <b>Discussion: </b>These findings are suggestive of support for this recruitment approach. Pilot testing will inform feasibility, effectiveness and process improvements.
DOI: 10.25402/nmt.25151717
title: Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures

description: Aim: This prospective, multicenter, open-label, noninterventional 12-week study investigated the effectiveness and tolerability of add-on nabiximols oromucosal spray (Sativex) in the real-world setting in Germany. Patients & methods: The main analysis set comprised 51 adult patients (49 nabiximols responders) with multiple sclerosis (MS) spasticity. Results: The mean overall goal attainment scale score (primary outcome measure) increased by 46% from baseline to week 12 (35.2 vs 51.4; p &lt; 0.001). Mean gait speed was improved by 23% at 4 and 12 weeks. Clinically meaningful improvements in mean 0– 10 numerical rating scale scores for spasticity, pain, sleep quality and urinary bladder dysfunction were recorded at 4 and 12 weeks. Conclusion: Nabiximols is a useful therapeutic option for patients with MS spasticity. Plain language summary: People with multiple sclerosis (MS) spasticity experience a variety of symptoms and have individual expectations about a new treatment. This study investigated patients’ perceptions about the effectiveness and tolerability of nabiximols oromucosal spray (Sativex) when added to current medications for spasticity. Common treatment goals for patients (n = 51) were less pain, better walking and improved sleep. After 12 weeks of treatment, 62% of selected treatment goals were achieved ‘as expected’ or ‘better than expected’ and 65% of patients considered their spasticity to be ‘much improved’. Meaningful improvements were recorded in spasticity-related symptoms of pain, sleep quality and bladder problems. Few side effects were reported. Nabiximols may be useful for MS patients with a poor response to usual spasticity medications.
DOI: 10.25402/nmt.25151717.v1
title: Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures

description: Aim: This prospective, multicenter, open-label, noninterventional 12-week study investigated the effectiveness and tolerability of add-on nabiximols oromucosal spray (Sativex) in the real-world setting in Germany. Patients & methods: The main analysis set comprised 51 adult patients (49 nabiximols responders) with multiple sclerosis (MS) spasticity. Results: The mean overall goal attainment scale score (primary outcome measure) increased by 46% from baseline to week 12 (35.2 vs 51.4; p &lt; 0.001). Mean gait speed was improved by 23% at 4 and 12 weeks. Clinically meaningful improvements in mean 0– 10 numerical rating scale scores for spasticity, pain, sleep quality and urinary bladder dysfunction were recorded at 4 and 12 weeks. Conclusion: Nabiximols is a useful therapeutic option for patients with MS spasticity. Plain language summary: People with multiple sclerosis (MS) spasticity experience a variety of symptoms and have individual expectations about a new treatment. This study investigated patients’ perceptions about the effectiveness and tolerability of nabiximols oromucosal spray (Sativex) when added to current medications for spasticity. Common treatment goals for patients (n = 51) were less pain, better walking and improved sleep. After 12 weeks of treatment, 62% of selected treatment goals were achieved ‘as expected’ or ‘better than expected’ and 65% of patients considered their spasticity to be ‘much improved’. Meaningful improvements were recorded in spasticity-related symptoms of pain, sleep quality and bladder problems. Few side effects were reported. Nabiximols may be useful for MS patients with a poor response to usual spasticity medications.
DOI: 10.25402/nmt.25610433
title: Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab

description: Aim: To assess time to improvement in Quality of Life in Neurological Disorders (Neuro-QoL) domains for patients treated with natalizumab versus ocrelizumab. Methods: Patients enrolled in the MS PATHS network who initiated treatment with either natalizumab or ocrelizumab rated the Neuro-QoL domains of physical function, symptoms, emotional health, cognitive function and social ability. Results: Time to clinically meaningful improvement was significantly shorter with natalizumab versus ocrelizumab for cognitive function (event time ratio [95% CI]: 0.37 [0.24–0.57]; p &lt; 0.001), sleep disturbance (0.45 [0.28– 0.72]; p = 0.001), social role participation (0.37 [0.21–0.66]; p = 0.001) and social role satisfaction (0.5 [0.31–0.8]; p = 0.004). Conclusion: Natalizumab had shorter time to clinically meaningful improvement in cognitive, sleep, and social role Neuro-QoL domains versus ocrelizumab. Plain language summary: Knowledge of treatment-related benefits associated with medication choices, including improvement of quality of life (QoL), are strong influential factors for patients to start and continue their therapies. Little is known about patient-reported time to onset of functional improvement upon the initiation of medications for multiple sclerosis (MS). The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) network, a repository of collaborative international data on routine MS management, includes patient-reported information on the health-related QoL using the Quality of Life in Neurological Disorders (Neuro-QoL) measure. This study included data from 883 eligible patients enrolled in MS PATHS, with the aim of assessing and comparing the time to improvement in physical, mental and social health for patients treated with natalizumab versus ocrelizumab using Neuro- QoL. Natalizumab and ocrelizumab are both high-efficacy treatment options for relapsing forms of MS. The results demonstrated that, compared with ocrelizumab, natalizumab treatment led to faster effect on mental and social health, as well as quicker improvements in physical functioning in the arms and hands. Overall, it took shorter time for natalizumab-treated patients to achieve better QoL compared with ocrelizumab. These findings highlight the importance of QoL in disease management and provide a patient perspective for healthcare providers when making decisions about high-efficacy treatments for their patients with MS.
DOI: 10.25402/nmt.25610433.v1
title: Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab

description: Aim: To assess time to improvement in Quality of Life in Neurological Disorders (Neuro-QoL) domains for patients treated with natalizumab versus ocrelizumab. Methods: Patients enrolled in the MS PATHS network who initiated treatment with either natalizumab or ocrelizumab rated the Neuro-QoL domains of physical function, symptoms, emotional health, cognitive function and social ability. Results: Time to clinically meaningful improvement was significantly shorter with natalizumab versus ocrelizumab for cognitive function (event time ratio [95% CI]: 0.37 [0.24–0.57]; p &lt; 0.001), sleep disturbance (0.45 [0.28– 0.72]; p = 0.001), social role participation (0.37 [0.21–0.66]; p = 0.001) and social role satisfaction (0.5 [0.31–0.8]; p = 0.004). Conclusion: Natalizumab had shorter time to clinically meaningful improvement in cognitive, sleep, and social role Neuro-QoL domains versus ocrelizumab. Plain language summary: Knowledge of treatment-related benefits associated with medication choices, including improvement of quality of life (QoL), are strong influential factors for patients to start and continue their therapies. Little is known about patient-reported time to onset of functional improvement upon the initiation of medications for multiple sclerosis (MS). The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) network, a repository of collaborative international data on routine MS management, includes patient-reported information on the health-related QoL using the Quality of Life in Neurological Disorders (Neuro-QoL) measure. This study included data from 883 eligible patients enrolled in MS PATHS, with the aim of assessing and comparing the time to improvement in physical, mental and social health for patients treated with natalizumab versus ocrelizumab using Neuro- QoL. Natalizumab and ocrelizumab are both high-efficacy treatment options for relapsing forms of MS. The results demonstrated that, compared with ocrelizumab, natalizumab treatment led to faster effect on mental and social health, as well as quicker improvements in physical functioning in the arms and hands. Overall, it took shorter time for natalizumab-treated patients to achieve better QoL compared with ocrelizumab. These findings highlight the importance of QoL in disease management and provide a patient perspective for healthcare providers when making decisions about high-efficacy treatments for their patients with MS.
DOI: 10.25402/nmt.25651617
title: Medicinal cannabis in neurodegenerative disorders: an open label, dose finding, safety and efficacy study

description: <b>Aim: </b>Currently, there exist no curative treatments for neurodegenerative disorders. Recently, there has been a resurgence of interest in the use of medicinal cannabis to improve neurological conditions. <b>Methods: </b>A 12-month, open label, dose-finding, safety and efficacy study was conducted including 48 subjects with a variety of neurodegenerative disorders. <b>Results: </b>In our participants, we observed a reduction in pain, improved sleep, enhanced well-being and less agitation. <b>Conclusion: </b>Our findings suggest that medicinal cannabis might be useful in patients with neurodegenerative disorders in controlling pain, enhancing sleep, reducing difficult behaviors, controlling unusual and complex symptoms when other treatments have failed – this offers medicinal cannabis a role in palliation.
DOI: 10.15468/dl.6pbyxm
title: Occurrence Download

description: A dataset containing 3112 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is one of (Acacia podalyriifolia A.Cunn. ex G.Don)"
 ]
}

 The dataset includes 3112 records from 177 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020010-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.4pkemy
title: Occurrence Download

description: A dataset containing 2439 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is one of (Strigosella africana (L.) Botsch.)"
 ]
}

 The dataset includes 2439 records from 153 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020012-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.24559486
title: <b>Carbon Release</b>

description: We performed an in-depth examination of the Late Pleistocene coevolution of organic carbon remobilisation and ice sheet expansion, by adding more high-resolution records of organic carbon burial on the East Siberia-Alaska continental margin. The main objective was the quantitative estimation of the extent of organic carbon remobilisation using a reconstruction approach to determine the total organic carbon (TOC) fluxes to the seafloor. The goal was to determine the contribution of dissolved inorganic carbon (DIC) released from remobilised organic carbon degradation to the Arctic Ocean and northern Nordic Seas carbon sink capacity, and thus to atmospheric CO<sub>2</sub> levels.
DOI: 10.15468/dl.hsnpc2
title: Occurrence Download

description: A dataset containing 7 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Thalamita indistincta Apel & Spiridonov, 1998"
 ]
}

 The dataset includes 7 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020011-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.24559486.v1
title: <b>Carbon Release</b>

description: We performed an in-depth examination of the Late Pleistocene coevolution of organic carbon remobilisation and ice sheet expansion, by adding more high-resolution records of organic carbon burial on the East Siberia-Alaska continental margin. The main objective was the quantitative estimation of the extent of organic carbon remobilisation using a reconstruction approach to determine the total organic carbon (TOC) fluxes to the seafloor. The goal was to determine the contribution of dissolved inorganic carbon (DIC) released from remobilised organic carbon degradation to the Arctic Ocean and northern Nordic Seas carbon sink capacity, and thus to atmospheric CO<sub>2</sub> levels.
DOI: 10.15468/dl.xzxxsr
title: Occurrence Download

description: A dataset containing 2054 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is one of (Acacia provincialis A.Camus)"
 ]
}

 The dataset includes 2054 records from 25 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020013-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.mshr9e
title: Occurrence Download

description: A dataset containing 542 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is one of (Strobilanthes alternata (Burm.fil.) Moylan ex J.R.I.Wood)"
 ]
}

 The dataset includes 542 records from 99 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020014-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.bs5n26
title: Occurrence Download

description: A dataset containing 217 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Portunus segnis (Forskål, 1775)"
 ]
}

 The dataset includes 217 records from 12 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020015-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.fehvmx
title: Occurrence Download

description: A dataset containing 1028 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Artemisia argyi H.Lév. & Vaniot"
 ]
}

 The dataset includes 1028 records from 38 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020016-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.79zbex
title: Occurrence Download

description: A dataset containing 50 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is BOLD:ADW7264"
 ]
}

 The dataset includes 50 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020019-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.n9qzrz
title: Occurrence Download

description: A dataset containing 2139 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is one of (Struchium sparganophorum (L.) Kuntze)"
 ]
}

 The dataset includes 2139 records from 159 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020018-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ypg3f6
title: Occurrence Download

description: A dataset containing 29037 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is one of (Acacia pycnantha Benth.)"
 ]
}

 The dataset includes 29037 records from 153 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020017-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.11199434
title: Svalbox-DOM_2024-0012

description: Model description: Digital outcrop model of Bollen's northern exposure.Data availability:All uploaded archives are to be extracted to the same directory for a functional working environment, i.e., at the very least consisting of a project folder with the data and metashape subdirectories. The included processing report specifies the processing parameters that were used as input for the processing software (Agisoft Metashape, v2.1.0.17532).Exported model data use CRS epsg:32633.Show and visualise on Svalbox.no:Through Svalbox we aim to take geoscientific research and education to the next level – with the simple motto of placing all key information and data sets in their correct spatial position. We bring modern technology, in particular cost-effective digital outcrops, to complement more than 200 years of geoscientific research on Svalbard. Finally, Svalbox provides a sustainable platform for sharing results, workflows and teaching material with the wider geoscientific community.For more information, contact the Svalbox team at svalbox[at]gmail.com.This data set forms part of the Svalbox Digital Model Database.Please cite the database alongside this resource:Betlem, Peter and Rodes, Nil and Birchall, Thomas and Dahlin, Anders and Smyrak-Sikora, Aleksandra and Senger, Kim. The Svalbox Digital Model Database: A Geoscientific Window into the High Arctic. Geosphere (2023) 19 (6): 1640-1666. https://doi.org/10.1130/GES02606.1
DOI: 10.5281/zenodo.11199435
title: Svalbox-DOM_2024-0012

description: Model description: Digital outcrop model of Bollen's northern exposure.Data availability:All uploaded archives are to be extracted to the same directory for a functional working environment, i.e., at the very least consisting of a project folder with the data and metashape subdirectories. The included processing report specifies the processing parameters that were used as input for the processing software (Agisoft Metashape, v2.1.0.17532).Exported model data use CRS epsg:32633.Show and visualise on Svalbox.no:Through Svalbox we aim to take geoscientific research and education to the next level – with the simple motto of placing all key information and data sets in their correct spatial position. We bring modern technology, in particular cost-effective digital outcrops, to complement more than 200 years of geoscientific research on Svalbard. Finally, Svalbox provides a sustainable platform for sharing results, workflows and teaching material with the wider geoscientific community.For more information, contact the Svalbox team at svalbox[at]gmail.com.This data set forms part of the Svalbox Digital Model Database.Please cite the database alongside this resource:Betlem, Peter and Rodes, Nil and Birchall, Thomas and Dahlin, Anders and Smyrak-Sikora, Aleksandra and Senger, Kim. The Svalbox Digital Model Database: A Geoscientific Window into the High Arctic. Geosphere (2023) 19 (6): 1640-1666. https://doi.org/10.1130/GES02606.1